Citadel Advisors
KITE

Citadel Advisors’s Kite Pharma, Inc. KITE Stock Holding History

Citadel Advisors’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,400
Closed -$9.06M – 8821
2017
Q3 		$9.06M Sell
50,400
-11,800
-19% -$1.64M 0.01% 1693
2017
Q2 		$6.45M Buy
62,200
+2,300
+4% +$188K 0.01% 1851
2017
Q1 		$4.7M Buy
59,900
+32,100
+115% +$1.98M ﹤0.01% 2116
2016
Q4 		$1.25M Buy
27,800
+2,300
+9% +$113K ﹤0.01% 3564
2016
Q3 		$1.42M Buy
25,500
+4,900
+24% +$273K ﹤0.01% 3394
2016
Q2 		$1.03M Buy
20,600
+4,100
+25% +$201K ﹤0.01% 3517
2016
Q1 		$758K Buy
16,500
+900
+6% +$43.6K ﹤0.01% 3823
2015
Q4 		$961K Buy
15,600
+2,800
+22% +$197K ﹤0.01% 3634
2015
Q3 		$713K Sell
12,800
-6,400
-33% -$403K ﹤0.01% 4279
2015
Q2 		$1.17M Buy
19,200
+2,000
+12% +$114K ﹤0.01% 3756
2015
Q1 		$992K Sell
17,200
-11,200
-39% -$751K ﹤0.01% 3927
2014
Q4 		$1.64M Buy
+28,400
New +$1.2M ﹤0.01% 3159

Citadel Advisors's KITE Position: Q3 2017 in Review

Citadel Advisors sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 27,170 shares — an estimated $3.79M sold.

Citadel Advisors first reported a position in KITE in Q2 2014 and held it in 13 quarters. The position peaked at $34.5M in Q1 2016. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Citadel Advisors reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Citadel Advisors sold 27,170 Kite Pharma, Inc. shares in Q3 2017, an estimated $3.79M.
  • Citadel Advisors first reported a position in Kite Pharma, Inc. in Q2 2014 and held it in 13 quarters.
  • Citadel Advisors's Kite Pharma, Inc. position peaked at $34.5M in Q1 2016.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Citadel Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.